<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294552</url>
  </required_header>
  <id_info>
    <org_study_id>PTCy-2014</org_study_id>
    <nct_id>NCT02294552</nct_id>
  </id_info>
  <brief_title>Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT</brief_title>
  <official_title>High-dose Post-transplantation Cyclophosphamide as Graft Versus-host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivan S Moiseev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of high-dose post-transplantation cyclophosphomide as
      graft-versus-host disease (GVHD) prophylaxis after allogeneic stem cell transplantation in
      patients with different risk of GVHD. The risk-adapted strategy involves using single-agent
      cyclophosphomide in recipients of matched bone marrow graft, and combining cyclophosphomide
      with tacrolimus and mycophenolate mofetil in recipients of matched peripheral blood stem
      cells and mismatched bone marrow.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute and chronic GVHD, requiring treatment</measure>
    <time_frame>365 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary graft failure</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity based NCI CTC grades</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious complications, including analysis of severe bacterial, fungal and viral infections incidence</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoid Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Immune System Diseases</condition>
  <arm_group>
    <arm_group_label>Matched bone marrow graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched peripheral blood stem cells graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mismatched peripheral blood stem cells or bone marrow graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Matched bone marrow graft</arm_group_label>
    <arm_group_label>Matched peripheral blood stem cells graft</arm_group_label>
    <arm_group_label>Mismatched peripheral blood stem cells or bone marrow graft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <arm_group_label>Matched bone marrow graft</arm_group_label>
    <arm_group_label>Matched peripheral blood stem cells graft</arm_group_label>
    <arm_group_label>Mismatched peripheral blood stem cells or bone marrow graft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine monophosphate</intervention_name>
    <arm_group_label>Matched bone marrow graft</arm_group_label>
    <arm_group_label>Matched peripheral blood stem cells graft</arm_group_label>
    <arm_group_label>Mismatched peripheral blood stem cells or bone marrow graft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <arm_group_label>Matched peripheral blood stem cells graft</arm_group_label>
    <arm_group_label>Mismatched peripheral blood stem cells or bone marrow graft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <arm_group_label>Matched peripheral blood stem cells graft</arm_group_label>
    <arm_group_label>Mismatched peripheral blood stem cells or bone marrow graft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>Matched bone marrow graft</arm_group_label>
    <arm_group_label>Matched peripheral blood stem cells graft</arm_group_label>
    <arm_group_label>Mismatched peripheral blood stem cells or bone marrow graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have an indication for allogeneic hematopoietic stem cell
             transplantation

          -  Signed informed consent

          -  Patients with a donor available. The donor and recipient must be identical at at least
             one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and
             HLA-DQB1. A minimum match of 5/10 is required for related donor. A minimum match of
             8/10 is required for unrelated donor.

          -  No second tumors

          -  No severe concurrent illness

        Exclusion Criteria:

          -  Moderate or severe cardiac dysfunction, left ventricular ejection fraction &lt;50%

          -  Moderate or severe decrease in pulmonary function, FEV1 &lt;70% or DLCO&lt;70% of predicted

          -  Respiratory distress &gt;grade I

          -  Severe organ dysfunction: AST or ALT &gt;5 upper normal limits, bilirubin &gt;1.5 upper
             normal limits, creatinine &gt;2 upper normal limits

          -  Creatinine clearance &lt; 60 mL/min

          -  Uncontrolled bacterial or fungal infection at the time of enrollment

          -  Requirement for vasopressor support at the time of enrollment

          -  Karnofsky index &lt;30%

          -  Pregnancy

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris V Afanasyev, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Pavlov State Medical University of St. Petersburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>November 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Petersburg State Pavlov Medical University</investigator_affiliation>
    <investigator_full_name>Ivan S Moiseev</investigator_full_name>
    <investigator_title>Vice-director for science of R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation</investigator_title>
  </responsible_party>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <keyword>Antineoplastic Agents, Alkylating</keyword>
  <keyword>Myeloablative Agonists</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Allogeneic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antineoplastic Agents, Alkylating</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

